ANNX — Annexon Inc

Annexon Inc (ANNX) is a biotechnology company listed on NASDAQ. It is led by Douglas E. Love Esq., J.D., based in 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005, with about 103 employees. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Net income was -$54.9M. ANNX currently screens at market cap $268.1M.

Use this ANNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANNX SEC filings page. Lician reads the product cache first so this HTML stays unique to Annexon Inc even when a live quote feed is slow.